William N. Voss

William N. Voss

Auto-generated profile, based on publicly available information

William N. Voss

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Science
Verified
Journal Article
Open access
PDF file
WVWilliam N. Voss
William N. Voss
YHYixuan J. Hou
Yixuan J. Hou
NJNicole V. Johnson
Nicole V. Johnson
GDGeorge Delidakis
George Delidakis
JKJin Eyun Kim
Jin Eyun Kim
Gregory C. IppolitoGregory C. Ippolito
Gregory C. Ippolito
A public anti-COVID antibody repertoire: Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus's spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern. Science , abg5268, this issue p. 1108

1 December 2021 in Molecular Cell
Verified
Journal Article
Open access
KJKamyab Javanmardi
Kamyab Javanmardi
CCChia-Wei Chou
Chia-Wei Chou
CTCynthia I. Terrace
Cynthia I. Terrace
AAAnkur Annapareddy
Ankur Annapareddy
TKTamer Saad Kaoud
Tamer Saad Kaoud
IFIlya J. Finkelstein
Ilya J. Finkelstein
The SARS-CoV-2 spike protein is a critical component of vaccines and a target for neutralizing monoclonal antibodies (nAbs). Spike is also undergoing immunogenic selection with variants that increase infectivity and partially escape convalescent plasma. Here, we describe Spike Display, a high-throughput platform to rapidly characterize glycosylated spike ectodomains across multiple coronavirus-family proteins. We assayed ∼200 variant SARS-CoV-2 spikes for their expression, ACE2 binding, and recognition by 13 nAbs. An alanine scan of all five N-terminal domain (NTD) loops highlights a public epitope in the N1, N3, and N5 loops recognized by most NTD-binding nAbs. NTD mutations in variants of concern B.1.1.7 (alpha), B.1.351 (beta), B.1.1.28 (gamma), B.1.427/B.1.429 (epsilon), and B.1.617.2 (delta) impact spike expression and escape most NTD-targeting nAbs. Finally, B.1.351 and B.1.1.28 completely escape a potent ACE2 mimic. We anticipate that Spike Display will accelerate antigen design, deep scanning mutagenesis, and antibody epitope mapping for SARS-CoV-2 and other emerging viral threats.

1 August 2024 in Cell Reports Medicine
Verified
Journal Article
Open access
WVWilliam N. Voss
William N. Voss
MMMichael L. Mallory
Michael L. Mallory
PBPatrick O. Byrne
Patrick O. Byrne
JMJeffrey M. Marchioni
Jeffrey M. Marchioni
SKSean A. Knudson
Sean A. Knudson
Gregory C. IppolitoGregory C. Ippolito
Gregory C. Ippolito
We describe the molecular-level composition of polyclonal immunoglobulin G (IgG) anti-spike antibodies from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, vaccination, or their combination ("hybrid immunity") at monoclonal resolution. Infection primarily triggers S2/N-terminal domain (NTD)-reactive antibodies, whereas vaccination mainly induces anti-receptor-binding domain (RBD) antibodies. This imprint persists after secondary exposures wherein >60% of ensuing hybrid immunity derives from the original IgG pool. Monoclonal constituents of the original IgG pool can increase breadth, affinity, and prevalence upon secondary exposures, as exemplified by the plasma antibody SC27. Following a breakthrough infection, vaccine-induced SC27 gained neutralization breadth and potency against SARS-CoV-2 variants and zoonotic viruses (half-maximal inhibitory concentration [IC50] ∼0.1-1.75 nM) and increased its binding affinity to the protective RBD class 1/4 epitope (dissociation constant [KD] < 5 pM). According to polyclonal escape analysis, SC27-like binding patterns are common in SARS-CoV-2 hybrid immunity. Our findings provide a detailed molecular definition of immunological imprinting and show that vaccination can produce class 1/4 (SC27-like) IgG antibodies circulating in the blood.

24 April 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
HTHidetaka Tanno
Hidetaka Tanno
JMJonathan R. McDaniel
Jonathan R. McDaniel
CSChristopher A. Stevens
Christopher A. Stevens
WVWilliam N. Voss
William N. Voss
JLJie Li
Jie Li
GGGeorge Georgiou
George Georgiou
We report a simple and low-cost one-step high-throughput technology for sequencing the paired antibody/TCR repertoire.

28 July 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
JMJonathan R. McDaniel
Jonathan R. McDaniel
WVWilliam N. Voss
William N. Voss
GBGeorgina Bowyer
Georgina Bowyer
SRScott A. Rush
Scott A. Rush
ASAlexandra J. Spencer
Alexandra J. Spencer
Gregory C. IppolitoGregory C. Ippolito
Gregory C. Ippolito
The World Health Organization (WHO) recently recommended the programmatic use of the R21/Matrix-M vaccine for Plasmodium falciparum malaria prevention in children living in malaria-endemic areas. To determine its effects on humoral immunity, we conducted a proteomic analysis of polyclonal IgG antibodies directed against the NANP tetrapeptide of the circumsporozoite protein (CSP), which comprises the vaccine’s core immunogen. In 10 malaria-naïve adult volunteers, R21/Matrix-M induced polarized IgG anti-NANP repertoires, heavily skewed for IGHV3-30/3-33 genes bearing minimal somatic mutation, which remained static in composition following a controlled human malaria infection challenge. Notably, these vaccine-generated antibodies cross-reacted with another protective CSP epitope, the N-terminal junction region, despite its absence from the R21 construct. NANP-specific IGHV3-30/3-33 mAbs mined from polyclonal IgG repertoires blocked sporozoite invasion in vitro and prevented parasitemia in vivo. Overall, R21/Matrix-M elicits polarized, minimally mutated, polyclonal IgG responses that can target multiple protective CSP epitopes, offering molecular insight into the serological basis for its demonstrated efficacy against P. falciparum malaria.